Marinus Pharmaceuticals, Inc.

NasdaqGM:MRNS Stock Report

Market Cap: US$481.4m

Marinus Pharmaceuticals Management

Management criteria checks 3/4

Marinus Pharmaceuticals' CEO is Scott Braunstein, appointed in Aug 2019, has a tenure of 4.58 years. total yearly compensation is $3.13M, comprised of 18.9% salary and 81.1% bonuses, including company stock and options. directly owns 0.1% of the company’s shares, worth $505.04K. The average tenure of the management team and the board of directors is 3.3 years and 4.3 years respectively.

Key information

Scott Braunstein

Chief executive officer

US$3.1m

Total compensation

CEO salary percentage18.9%
CEO tenure4.6yrs
CEO ownership0.1%
Management average tenure3.3yrs
Board average tenure4.3yrs

Recent management updates

Recent updates

Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) Analysts Are Cutting Their Estimates: Here's What You Need To Know

Mar 08
Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) Analysts Are Cutting Their Estimates: Here's What You Need To Know

Does Marinus Pharmaceuticals (NASDAQ:MRNS) Have A Healthy Balance Sheet?

Dec 22
Does Marinus Pharmaceuticals (NASDAQ:MRNS) Have A Healthy Balance Sheet?

Is Marinus Pharmaceuticals (NASDAQ:MRNS) Using Debt Sensibly?

Sep 22
Is Marinus Pharmaceuticals (NASDAQ:MRNS) Using Debt Sensibly?

Why Investors Shouldn't Be Surprised By Marinus Pharmaceuticals, Inc.'s (NASDAQ:MRNS) P/S

Jun 12
Why Investors Shouldn't Be Surprised By Marinus Pharmaceuticals, Inc.'s (NASDAQ:MRNS) P/S

Forecast: Analysts Think Marinus Pharmaceuticals, Inc.'s (NASDAQ:MRNS) Business Prospects Have Improved Drastically

May 16
Forecast: Analysts Think Marinus Pharmaceuticals, Inc.'s (NASDAQ:MRNS) Business Prospects Have Improved Drastically

Analysts Just Made A Major Revision To Their Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) Revenue Forecasts

Oct 26
Analysts Just Made A Major Revision To Their Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) Revenue Forecasts

Is Marinus Pharmaceuticals (NASDAQ:MRNS) Weighed On By Its Debt Load?

Oct 12
Is Marinus Pharmaceuticals (NASDAQ:MRNS) Weighed On By Its Debt Load?

Marinus Pharmaceuticals: Positive News Flow Of Note

Sep 22

Marinus Pharma closes on sale of a U.S. FDA priority review voucher for $110M

Aug 29

Analysts' Revenue Estimates For Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) Are Surging Higher

Aug 13
Analysts' Revenue Estimates For Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) Are Surging Higher

Marinus Pharmaceuticals Q2 2022 Earnings Preview

Aug 10

Marinus Pharma announces U.S. commercial launch of seizure therapy Ztalmy

Jul 28

Revisiting Marinus Pharmaceuticals

May 05

Need To Know: Analysts Are Much More Bullish On Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) Revenues

Mar 27
Need To Know: Analysts Are Much More Bullish On Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) Revenues

Does Marinus Pharmaceuticals (NASDAQ:MRNS) Have A Healthy Balance Sheet?

Mar 03
Does Marinus Pharmaceuticals (NASDAQ:MRNS) Have A Healthy Balance Sheet?

Marinus Stock Slides To 18-Month Low, Upcoming PDUFA May Offer Redemption

Feb 28

Health Check: How Prudently Does Marinus Pharmaceuticals (NASDAQ:MRNS) Use Debt?

Nov 04
Health Check: How Prudently Does Marinus Pharmaceuticals (NASDAQ:MRNS) Use Debt?

Marinus Pharmaceuticals (MRNS) Investor Presentation - Slideshow

May 26

We're Hopeful That Marinus Pharmaceuticals (NASDAQ:MRNS) Will Use Its Cash Wisely

Apr 14
We're Hopeful That Marinus Pharmaceuticals (NASDAQ:MRNS) Will Use Its Cash Wisely

Marinus Pharmaceuticals, Inc.'s (NASDAQ:MRNS) Intrinsic Value Is Potentially 53% Above Its Share Price

Mar 10
Marinus Pharmaceuticals, Inc.'s (NASDAQ:MRNS) Intrinsic Value Is Potentially 53% Above Its Share Price

CEO Compensation Analysis

How has Scott Braunstein's remuneration changed compared to Marinus Pharmaceuticals's earnings?
DateTotal CompensationSalaryCompany Earnings
Dec 31 2023n/an/a

-US$141m

Sep 30 2023n/an/a

-US$134m

Jun 30 2023n/an/a

-US$28m

Mar 31 2023n/an/a

-US$35m

Dec 31 2022US$3mUS$591k

-US$20m

Sep 30 2022n/an/a

-US$14m

Jun 30 2022n/an/a

-US$105m

Mar 31 2022n/an/a

-US$91m

Dec 31 2021US$4mUS$574k

-US$99m

Sep 30 2021n/an/a

-US$88m

Jun 30 2021n/an/a

-US$84m

Mar 31 2021n/an/a

-US$76m

Dec 31 2020US$4mUS$556k

-US$76m

Sep 30 2020n/an/a

-US$74m

Jun 30 2020n/an/a

-US$72m

Mar 31 2020n/an/a

-US$69m

Dec 31 2019US$2mUS$305k

-US$54m

Sep 30 2019n/an/a

-US$49m

Jun 30 2019n/an/a

-US$46m

Mar 31 2019n/an/a

-US$43m

Dec 31 2018US$210kn/a

-US$37m

Compensation vs Market: Scott's total compensation ($USD3.13M) is above average for companies of similar size in the US market ($USD2.19M).

Compensation vs Earnings: Scott's compensation has been consistent with company performance over the past year.


CEO

Scott Braunstein (60 yo)

4.6yrs

Tenure

US$3,131,996

Compensation

Dr. Scott N. Braunstein, M.D., serves as an Independent Director at Caribou Biosciences, Inc. since June 2021. He served as Director at Protara Therapeutics, Inc. (formerly known as ArTara Therapeutics, In...


Leadership Team

NamePositionTenureCompensationOwnership
Scott Braunstein
CEO, President & Chairman4.6yrsUS$3.13m0.10%
$ 505.0k
Steven Pfanstiel
COO, CFO & Treasurer2.9yrsUS$1.43m0.023%
$ 112.1k
Joseph Hulihan
Chief Medical Officer4.4yrsUS$1.52m0.023%
$ 109.3k
Alex Aimetti
Chief Scientific Officerno datano datano data
Sonya Weigle
Senior VP of Investor Relationsless than a yearno datano data
Martha Manning
Senior VP3.8yrsno data0.0057%
$ 27.4k
Molly Cameron
Director of Corporate Communications & Investor Relationsless than a yearno datano data
Kimberly McCormick
Chief Regulatory & Quality Assurance Officerno datano datano data
Thomas Lyons
Chief Business Officerno datano datano data
Christina Shafer
Chief Commercial Officer3.3yrsno data0.018%
$ 84.8k
David Czekai
Senior Vice President of Chemistryno datano datano data
Mark Paternoster
Senior Vice President of Developmentno datano datano data

3.3yrs

Average Tenure

60yo

Average Age

Experienced Management: MRNS's management team is considered experienced (3.3 years average tenure).


Board Members

NamePositionTenureCompensationOwnership
Scott Braunstein
CEO, President & Chairman5.5yrsUS$3.13m0.10%
$ 505.0k
Timothy Mayleben
Lead Independent Director15.3yrsUS$210.31k0.025%
$ 122.2k
Elan Ezickson
Independent Director4.3yrsUS$200.64k0.0037%
$ 17.6k
Jacqueline A. French
Member of Scientific Advisory Boardno datano datano data
Seth H. Fischer
Independent Director7.5yrsUS$189.47k0.0044%
$ 21.4k
Saraswathy Nochur
Independent Director3yrsUS$193.81k0.0050%
$ 24.2k
Michael Rogawski
Member of Scientific Advisory Boardno datano datano data
Charles Austin
Independent Director3.7yrsUS$195.64k0.0031%
$ 14.8k
Christine Silverstein
Independent Director1.2yrsno datano data
Eugen Trinka
Member of Scientific Advisory Boardno datano datano data
Elizabeth Thiele
Member of Scientific Advisory Boardno datano datano data
Nicola Specchio
Member of Scientific Advisory Boardno datano datano data

4.3yrs

Average Tenure

61yo

Average Age

Experienced Board: MRNS's board of directors are considered experienced (4.3 years average tenure).


Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.